Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2
© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH..
Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT , are first generated by grafting an anti-RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo-EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high-avidity neutralizing interaction. Then, by C-terminal fusion of an anti-DNGR-1 scFv to TNT , the bispecific trimerbody TNT DNGR-1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross-priming. Therapeutic administration of TNT DNGR-1, but not TNT , protects K18-hACE2 mice from a lethal SARS-CoV-2 infection, boosting virus-specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus-neutralizing antibody activity and demonstrate the therapeutic potential of the Fc-free strategy that can be used advantageously to provide both immediate and long-term protection against SARS-CoV-2 and other viral infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 10(2023), 34 vom: 30. Dez., Seite e2304818 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 11.12.2023 Date Revised 11.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/advs.202304818 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363561579 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363561579 | ||
| 003 | DE-627 | ||
| 005 | 20231227131809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/advs.202304818 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM363561579 | ||
| 035 | |a (NLM)37863812 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lázaro-Gorines, Rodrigo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.12.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Advanced Science published by Wiley-VCH GmbH. | ||
| 520 | |a Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT , are first generated by grafting an anti-RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo-EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high-avidity neutralizing interaction. Then, by C-terminal fusion of an anti-DNGR-1 scFv to TNT , the bispecific trimerbody TNT DNGR-1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross-priming. Therapeutic administration of TNT DNGR-1, but not TNT , protects K18-hACE2 mice from a lethal SARS-CoV-2 infection, boosting virus-specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus-neutralizing antibody activity and demonstrate the therapeutic potential of the Fc-free strategy that can be used advantageously to provide both immediate and long-term protection against SARS-CoV-2 and other viral infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTL responses | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a bispecific trimerbody | |
| 650 | 4 | |a cross-priming | |
| 650 | 4 | |a dendritic cells | |
| 650 | 4 | |a neutralizing antibody | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Pérez, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Heras-Murillo, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Adán-Barrientos, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Albericio, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Astorgano, David |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Luczkowiak, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Labiod, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Harwood, Seandean L |e verfasserin |4 aut | |
| 700 | 1 | |a Segura-Tudela, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio-Pérez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Nugraha, Yudhi |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Xiaoran |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuxing |e verfasserin |4 aut | |
| 700 | 1 | |a Alfonso, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Adipietro, Kaylin A |e verfasserin |4 aut | |
| 700 | 1 | |a Abeyawardhane, Dinendra L |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Compte, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Wenbo |e verfasserin |4 aut | |
| 700 | 1 | |a MacKerell, Alexander D |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Francisco J |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a Pozharski, Edwin |e verfasserin |4 aut | |
| 700 | 1 | |a Godoy-Ruiz, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Inés G |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho, David |e verfasserin |4 aut | |
| 700 | 1 | |a García-Arriaza, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Vallina, Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced science (Weinheim, Baden-Wurttemberg, Germany) |d 2014 |g 10(2023), 34 vom: 30. Dez., Seite e2304818 |w (DE-627)NLM252851455 |x 2198-3844 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:34 |g day:30 |g month:12 |g pages:e2304818 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/advs.202304818 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 34 |b 30 |c 12 |h e2304818 | ||